[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.255.49. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Olfson  MKlerman  GL Trends in the prescription of antidepressants by office-based psychiatrists.  Am J Psychiatry 1993;150571- 577PubMedGoogle Scholar
2.
Thase  MEKupfer  DJ Recent developments in the pharmacotherapy of mood disorders.  J Consult Clin Psychol 1996;64646- 659PubMedGoogle ScholarCrossref
3.
Beck  ATRush  AJShaw  BFEmery  G Cognitive Therapy of Depression.  New York, NY Guilford Press1979;
4.
American Psychiatric Association, Practice guideline for the treatment of patients with major depressive disorder (revision).  Am J Psychiatry 2000;157 ((suppl 4)) 1- 45PubMedGoogle Scholar
5.
Rush  AJBeck  ATKovacs  MHollon  S Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed patients.  Cognit Ther Res 1977;117- 37Google ScholarCrossref
6.
Elkin  IShea  MTWatkins  JTImber  SDSotsky  SMCollins  JFGlass  DRPilkonis  PALeber  WRDocherty  JPFiester  SJParloff  MB NIMH Treatment of Depression Collaborative Research Program: general effectiveness of treatments.  Arch Gen Psychiatry 1989;46971- 982PubMedGoogle ScholarCrossref
7.
Elkin  IGibbons  RDShea  MTSotsky  SMWatkins  JTPilkonis  PAHedeker  D Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program.  J Consult Clin Psychol 1995;63841- 847PubMedGoogle ScholarCrossref
8.
Jacobson  NSHollon  SD Cognitive-behavior therapy versus pharmacotherapy:now that the jury's returned its verdict, it's time to present the rest of the evidence.  J Consult Clin Psychol 1996;6474- 80PubMedGoogle ScholarCrossref
9.
Murphy  GESimons  ADWetzel  RDLustman  PJ Cognitive therapy and pharmacotherapy.  Arch Gen Psychiatry 1984;4133- 41PubMedGoogle ScholarCrossref
10.
Hollon  SDDeRubeis  RJEvans  MDWiemer  MJGarvey  MJGrove  WMTuason  VB Cognitive therapy and pharmacotherapy for depression: singly and in combination.  Arch Gen Psychiatry 1992;49774- 781PubMedGoogle ScholarCrossref
11.
DeRubeis  RJGelfand  LATang  TZSimons  AD Medications versus cognitive behavioral therapy for severely depressed outpatients: mega-analysis of four randomized comparisons.  Am J Psychiatry 1999;1561007- 1013PubMedGoogle Scholar
12.
First  MBSpitzer  RLGibbon  MWilliams  JBW Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN).  New York Biometrics Research, New York State Psychiatric Institute2001;
13.
Spitzer  RLWilliams  JBWGibbon  MFirst  MB Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II, Version 1.0).  Washington, DC American Psychiatric Press1990;
14.
Hamilton  M A rating scale for depression.  J Neurol Neurosurg Psychiatry 1960;2356- 62PubMedGoogle ScholarCrossref
15.
Williams  JB A structured interview guide for the Hamilton Depression Rating Scale.  Arch Gen Psychiatry 1988;45742- 747PubMedGoogle ScholarCrossref
16.
Reimherr  FWAmsterdam  JDQuitkin  FMRosenbaum  JFFava  MZajecka  JBeasley  CMMichelson  DRoback  PSundell  K Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.  Am J Psychiatry 1998;1551247- 1253PubMedGoogle Scholar
17.
Fleiss  JLCohen  J Statistical Methods for Rates and Proportions.  New York John Wiley & Sons1973;
18.
American Psychological Association, Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC American Psychological Association1994;
19.
Hollon  SDDeRubeis  RJShelton  RCAmsterdam  JDSalomon  RMO’Reardon  JPLovett  MLYoung  PRHaman  KLFreeman  BBGallop  R Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.  Arch Gen Psychiatry 2005;62417- 422Google ScholarCrossref
20.
Hollon  SDThase  MEMarkowitz  JC Treatment and prevention of depression.  Psychological Science in the Public Interest 2002;339- 77Google ScholarCrossref
21.
Fawcett  JEpstein  PFiester  SJElkin  IAutry  JH Clinical management-imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program.  Psychopharmacol Bull 1987;23309- 324PubMedGoogle Scholar
22.
Beck  JS Cognitive Therapy: Basics and Beyond.  New York, NY Guilford Press1995;
23.
Beck  ATFreeman  A Cognitive Therapy of Personality Disorders.  New York, NY Guilford Press1990;
24.
Amsterdam  JDBrunswick  DJGilbertini  M Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.  J Psychiatr Res 2004;38259- 265PubMedGoogle ScholarCrossref
25.
Frank  EPrien  RFJarrett  RBKeller  MBKupfer  DJLavori  PWRush  AJWeissman  MM Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence.  Arch Gen Psychiatry 1991;48851- 855PubMedGoogle ScholarCrossref
26.
Kuritz  SJLandis  JRKoch  GG A General overview of Mantel-Haenszel methods: applications and recent developments.  Annu Rev Public Health 1988;9123- 160PubMedGoogle ScholarCrossref
27.
Hosmer  DWLemeshow  S Applied Logistic Regression.  New York Wiley1989;
28.
Stokes  MEDavis  CSKoch  GG Categorical Data Analysis Using the SAS System.  Cary, NC SAS Institute Inc1995;
29.
Bryk  ARaudenbush  S Hierarchical Linear Modeling: Applications and Data Analysis Methods.  Newbury Park, Calif Sage Publishing1996;
30.
Goldstein  H Models in Educational and Social Research.  New York, NY Oxford University Press1987;
31.
Raudenbush  SWXiao-Feng  L Effects of study duration, frequency of observation, and sample size on power in studies of group differences in polynomial change.  Psychol Methods 2001;6387- 401PubMedGoogle ScholarCrossref
32.
Cohen  J Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ Lawrence Erlbaum Associates1988;
33.
Klein  DF Preventing hung juries about therapy studies.  J Consult Clin Psychol 1996;6474- 80PubMedGoogle ScholarCrossref
34.
Jacobson  NSHollon  SD Prospects for future comparisons between drugs and psychotherapy: lessons from the CBT-versus-pharmacotherapy exchange.  J Consult Clin Psychol 1996;64104- 108PubMedGoogle ScholarCrossref
Original Article
April 2005

Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression

Author Affiliations

Author Affiliations: Departments of Psychology (Dr DeRubeis), and Psychiatry (Drs Amsterdam, Young, O’Reardon, and Gladis), University of Pennsylvania, Philadelphia; Departments of Psychology (Dr Hollon), and Psychiatry (Drs Shelton, Salomon, Lovett, and Brown), Vanderbilt University, Nashville, Tenn; Department of Mathematics and Applied Statistics, West Chester University, West Chester, Pa (Dr Gallop).

Arch Gen Psychiatry. 2005;62(4):409-416. doi:10.1001/archpsyc.62.4.409
Abstract

Background  There is substantial evidence that antidepressant medications treat moderate to severe depression effectively, but there is less data on cognitive therapy’s effects in this population.

Objective  To compare the efficacy in moderate to severe depression of antidepressant medications with cognitive therapy in a placebo-controlled trial.

Design  Random assignment to one of the following: 16 weeks of medications (n = 120), 16 weeks of cognitive therapy (n = 60), or 8 weeks of pill placebo (n = 60).

Setting  Research clinics at the University of Pennsylvania, Philadelphia, and Vanderbilt University, Nashville, Tenn.

Patients  Two hundred forty outpatients, aged 18 to 70 years, with moderate to severe major depressive disorder.

Interventions  Some study subjects received paroxetine, up to 50 mg daily, augmented by lithium carbonate or desipramine hydrochloride if necessary; others received individual cognitive therapy.

Main Outcome Measure  The Hamilton Depression Rating Scale provided continuous severity scores and allowed for designations of response and remission.

Results  At 8 weeks, response rates in medications (50%) and cognitive therapy (43%) groups were both superior to the placebo (25%) group. Analyses based on continuous scores at 8 weeks indicated an advantage for each of the active treatments over placebo, each with a medium effect size. The advantage was significant for medication relative to placebo, and at the level of a nonsignificant trend for cognitive therapy relative to placebo. At 16 weeks, response rates were 58% in each of the active conditions; remission rates were 46% for medication, 40% for cognitive therapy. Follow-up tests of a site × treatment interaction indicated a significant difference only at Vanderbilt University, where medications were superior to cognitive therapy. Site differences in patient characteristics and in the relative experience levels of the cognitive therapists each appear to have contributed to this interaction.

Conclusion  Cognitive therapy can be as effective as medications for the initial treatment of moderate to severe major depression, but this degree of effectiveness may depend on a high level of therapist experience or expertise.

×